Skyline Builders vs Phoenix Asia
CRMN and PHOE side by side, both in industrials. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRMN and PHOE compare
Skyline Builders grew revenue faster over the last twelve months (8.9% versus −2.2% for Phoenix Asia).
Skyline Builders keeps more of each dollar of sales as profit, with a net margin of 18.1% compared with −16.7% at Phoenix Asia.
Skyline Builders scores higher on the StockData Score (7 against 5 for Phoenix Asia), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRMN | PHOE |
|---|---|---|
| Size and price | ||
| Share price | $0.822 | $16.29 |
| Change, 1 year | −72.7% | −3.0% |
| Beta (5Y) | 2.01 | 1.92 |
| Employees | 73 | 32 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 4 (better) | 0 |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 8.9% (better) | −2.2% |
| Net income growth (TTM) | 1146% (better) | −217% |
| EPS growth (TTM) | −836% | −200% (better) |
| Profitability | ||
| Gross margin | 6.6% (better) | 4.6% |
| Operating margin | −24.1% | −16.8% (better) |
| Net margin | 18.1% (better) | −16.7% |
| FCF margin | −6.1% | – |
| Return on equity | 20.6% (better) | −25.9% |
| Return on invested capital | −22.6% (better) | −31.9% |
| Financial health | ||
| Debt / equity | 0.15 (better) | 0.00 |
| Interest coverage | −739.1× | −487.7× (better) |
| Current ratio | 2.99 | 5.46 (better) |
| Piotroski F-score | 5 (better) | 2 |
| Ownership | ||
| Held by institutions | 12.2% | – |
| Held by insiders | 37.1% | 74.5% |
| Short interest, % of float | – | 0.02% |
Go deeper
- CRMN stock overview
- CRMN income statement
- CRMN valuation and score
- PHOE stock overview
- PHOE income statement
- PHOE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.